Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse

[1]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[2]  M. J. Ramaiah,et al.  BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer. , 2018 .

[3]  A. Avan,et al.  The 9p21 locus: A potential therapeutic target and prognostic marker in breast cancer , 2018, Journal of cellular physiology.

[4]  Weidong Wei,et al.  Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients , 2018, Disease markers.

[5]  H. Lo,et al.  Inhibiting TRK Proteins in Clinical Cancer Therapy , 2018, Cancers.

[6]  V. Barresi,et al.  Human Epidermal Growth Factor Receptor 2 Status in Gastric Carcinomas with Distinctive Prevalent Cribriform Component , 2018, Disease markers.

[7]  Nikhil Wagle,et al.  Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[9]  Troels Bechmann,et al.  Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review , 2017, Clinical chemistry and laboratory medicine.

[10]  Nikhil Wagle,et al.  Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors , 2017, Nature Communications.

[11]  Marc Tischkowitz,et al.  Clinical implications of germline mutations in breast cancer: TP53 , 2017, Breast Cancer Research and Treatment.

[12]  Qiang Yu,et al.  Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence , 2017, Nature Medicine.

[13]  Jiaming Liu,et al.  Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer , 2017, Scientific Reports.

[14]  N. Turner,et al.  Advances and challenges in targeting FGFR signalling in cancer , 2017, Nature Reviews Cancer.

[15]  S. Elledge,et al.  Aneuploidy in Cancer: Seq-ing Answers to Old Questions , 2017 .

[16]  R. Bernards,et al.  Targeting the RB-E2F pathway in breast cancer , 2016, Oncogene.

[17]  J. Hugh,et al.  MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad , 2015, Clinical & Experimental Metastasis.

[18]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[19]  G. Schmidt,et al.  Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase , 2015, British Journal of Cancer.

[20]  V. Wong,et al.  Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients , 2015, Proceedings of the National Academy of Sciences.

[21]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[22]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[23]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[24]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[25]  A. Luini,et al.  Prognostic role of CA15.3 in 7942 patients with operable breast cancer , 2012, Breast Cancer Research and Treatment.

[26]  Karl-Heinz Glatting,et al.  Genome-wide prediction of splice-modifying SNPs in human genes using a new analysis pipeline called AASsites , 2011, BMC Bioinformatics.

[27]  S. Sleijfer,et al.  Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes , 2011, Breast Cancer Research and Treatment.

[28]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[29]  A. Ashworth,et al.  FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.

[30]  Eric S. Lander,et al.  Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene , 2007, Cell.

[31]  D. Aguiar-Bujanda,et al.  False Elevation of Serum CA 15‐3 Levels in Patients Under Follow‐Up for Breast Cancer , 2004, The breast journal.

[32]  D. Kowbel,et al.  Characterization of the novel amplified in breast cancer-1 (NABC1) gene product. , 2003, Experimental cell research.

[33]  F. Guadagni,et al.  A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  G. Rey,et al.  Survival Analysis with Multiple Causes of Death: Extending the Competing Risks Model. , 2017, Epidemiology.

[35]  M. Lippman,et al.  Breast Cancer Research and Treatment , 2004, Breast Cancer Research and Treatment.